Role of chemokines and their receptors in chronic lymphocytic leukemia Function in microenvironment and targeted therapy

被引：32
|
作者：
Han, Ting-Ting [1 ]
Fan, Lei [1 ]
Li, Jian-Yong [1 ]
Xu, Wei [1 ]
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China
来源：
CANCER BIOLOGY & THERAPY | 2014年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
chronic leukemia lymphoma; microenvironment; chemokines; chemokines receptors; targeted therapy; B-CELL RECEPTOR; TYROSINE KINASE INHIBITOR; IN-VITRO; NODE MICROENVIRONMENT; GROWTH-FACTOR; PHASE-II; CXCR4; ACTIVATION; SURVIVAL; PCI-32765;
D O I：
10.4161/cbt.26607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chemokines produced in distinct tissue microenvironments sustain migration of mature lymphocytes in lymphoglandula. Chemokine receptors expressed on chronic lymphocytic leukemia (CLL) cells regulate the migration of the leukemia cells within the bone marrow (BM), lymphoid organs in collaboration with chemokines. Chemokines form a pro-survival circuitry by regulating leukocyte trafficking, maintaining extended lymphocyte survival. Therefore, chemokines in tumor cell-microenvironment interactions represent a target for treatment of CLL. AMD3100 disrupts the CLL/microenvironment interactions and influences CXCL12/CXCR4 survival signaling. Fostamatinib, ibrutinib, GS-1101 as B-cell receptor (BCR) related kinase inhibitors inhibit BCR- and chemokine-receptor-signal-regulated kinase and have a good clinical response in CLL. Lenalidomide, sorafenib, and dasatinib are other additional drugs associated with chemokine in microenvironment. Inhibiting signaling through chemokine and microenvironment associated signaling are emerging as innovative therapeutic targets in CLL. In this article, we reviewed the role of chemokines in CLL microenvironment and novel therapeutics targeting CLL microenvironment.
引用
收藏
页码：3 / 9
页数：7
相关论文
共 50 条
  • [41] Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia
    Pepe, Felice
    Balatti, Veronica
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (02)
  • [42] Role of the microenvironment in chronic lymphocytic leukaemia
    Caligaris-Cappio, F
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (03) : 380 - 388
  • [43] Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era
    Hampel, Paul J.
    Rabe, Kari G.
    Wang, Yucai
    Hwang, Steven R.
    Kenderian, Saad S.
    Muchtar, Eli
    Leis, Jose F.
    Koehler, Amber B.
    Tsang, Mazie
    Hilal, Talal
    Parrondo, Ricardo
    Bailen, Rachel J.
    Schwager, Susan M.
    Hanson, Curtis A.
    Braggio, Esteban
    Slager, Susan L.
    Shi, Min
    Zepeda-Mendoza, Cinthya J.
    Van Dyke, Daniel L.
    Shanafelt, Tait D.
    King, Rebecca L.
    Call, Timothy G.
    Kay, Neil E.
    Ding, Wei
    Parikh, Sameer A.
    LEUKEMIA, 2025, 39 (02) : 503 - 507
  • [44] EXPLORING THE ROLE AND USE OF CANNABINOID RECEPTORS AND CANNABINOIDS IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Weiss, P.
    Porpaczy, E.
    Le, T.
    Skrabs, C.
    Gruber, M.
    Pausz, C.
    Jaeger, U.
    Vanura, K.
    HAEMATOLOGICA, 2013, 98 : 290 - 291
  • [45] Extracellular Vesicles in Chronic Lymphocytic Leukemia: Tumor Microenvironment Messengers as a Basis for New Targeted Therapies?
    Dubois, Kenza
    Tannoury, Mariana
    Bauvois, Brigitte
    Susin, Santos A.
    Garnier, Delphine
    CANCERS, 2023, 15 (08)
  • [46] Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting
    Burger, Jan A.
    SEMINARS IN CANCER BIOLOGY, 2010, 20 (06) : 424 - 430
  • [47] THE ROLE OF MAINTENANCE THERAPY IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Kuvshinov, A.
    Voloshin, S.
    Martynkevich, I.
    Garifullin, A.
    Kleina, E.
    HAEMATOLOGICA, 2017, 102 : 717 - 717
  • [48] Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy
    Molica, Stefano
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (11) : 803 - 806
  • [49] Will combination therapy with targeted drugs be better for achieving remission in chronic lymphocytic leukemia?
    Robak, Tadeusz
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (16) : 1675 - 1678
  • [50] Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia
    Mukaida, Naofumi
    Tanabe, Yamato
    Baba, Tomohisa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
12345